Ransomware Intelligence

    Latest Research on INC and The Gentlemen Ransomware: Exposed AI Infrastructure

    Read the Research

    Asensus Surgical Ransomware Attack

    asensus.comRansomed

    United StatesCountry
    Oct 20, 2026Discovered

    About this victim

    About Asensus Surgical TransEnterix, which rebranded as Asensus Surgical in 2021, pursued the goal of challenging Intuitive Surgical in the robotic surgery market. After the FDA rejected its SurgiBot system in 2016, the company pivoted to the Senhance platform, a digital laparoscopy system featuring haptic feedback and eye-tracking camera control. Despite building a global procedure base, Asensus faced persistent financial difficulties and going-concern doubts, ultimately being acquired by KARL STORZ in 2024. The acquisition marked the end of Asensus as an independent entity, with its Senhance technology now folded into KARL STORZ's broader surgical portfolio. Asensus Surgical fell victim to a cyberattack, resulting in the theft of more than 600 GB of data and over 85,000 files containing confidential information, employees’ personal documents, research findings, and all of the company’s internal information.

    Domain

    asensus.com

    Industry

    Healthcare

    Country

    United States

    Discovered

    28 days ago

    Attack date

    Oct 20, 2026

    Confidence

    100%

    Severity

    Medium

    Status

    Claimed

    Threat group

    dark project

    Total victims

    31

    First seen

    Aug 2026

    Last seen

    Nov 2026

    Group status

    active

    Sophistication

    0

    Impact score

    70

    Threat level

    5.1/10
    Aggressiveness8/10
    Lethality2.7/10
    Criticality4.6/10

    Status breakdown

    Data Leaked3.2%1
    Claimed
    this victim
    96.8%30

    Victim's position within group

    Industry

    Healthcare

    Known target sector

    Country

    United States

    Frequently targeted country

    Group activity

    Monthly attacks · dark project

    31

    total · avg 7.8/mo